Evaluation of Bone Turnover in Epileptic Children Using Oxcarbazepine


Cansu A., Yesilkaya E., SERDAROĞLU A. , HIRFANOĞLU T. , Camurdan O., Gulbahar Ö. , ...Daha Fazla

PEDIATRIC NEUROLOGY, cilt.39, ss.266-271, 2008 (SCI İndekslerine Giren Dergi) identifier identifier identifier

Özet

This study evaluated the effects of oxcarbazepine monotherapy on bone turnover in prepubertal and pubertal children. Thirty-four newly diagnosed pediatric patients with normal bone mineral density, serum biochemical markers of bone formation, and hormonal markers participated. Levels of 25-hydroxyvitamin D were significantly decreased after therapy compared with baseline values. Levels of gamma-glutamyl transferase, phosphorus, alkaline phosphatase, osteocalcin, parathyroid hormone, and calcitonin had increased. However, only changes in osteocalcin and gamma-glutamyl transferase levels were statistically significant compared with baseline values. Drug-induced osteopenia was evident in 3 patients with z scores of bone-mineral density less than -2.0, whereas these patients had z scores of less than -1.5 before treatment. Although 18 months of oxcarbazepine treatment exerted slightly adverse effects on bone metabolism, the effect seems insignificant in children with normal bone-mineral density. Although alterations in bone metabolism do not always suffice to explain the decrease in bonemineral metabolism, we think that patients with osteopenia before the initiation of oxcarbazepine therapy should be followed carefully, especially in long-term treatment. (C) 2008 Published by Elsevier Inc.